Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Somatostatin (SST), a growth hormone inhibitory peptide, is expressed in endocrine and
non-endocrine tissues, immune cells and the central nervous system (CNS). Post-release …

Somatostatin (SST), a regulatory peptide, is produced by neuroendocrine, inflammatory, and
immune cells in response to ions, nutrients, neuropeptides, neurotransmitters, thyroid and …

In the past few years, nuclear DNA damage-sensing mechanisms activated by ionizing
radiation have been identified, including ATM/ATR and the DNA-dependent protein kinase …

Somatostatins—also known as somatotropin-release inhibiting factors (SRIFs)—are a family
of cyclopeptides that have broad inhibitory effects on the secretion of hormones such as …

Cholecystokinin and gastrin receptors (CCK1R and CCK2R) are G protein-coupled
receptors that have been the subject of intensive research in the last 10 years with …

Somatostatin (SST) potently inhibits insulin and glucagon release from pancreatic islets.
Five distinct membrane receptors (SSTR1–5) for SST are known, and at least two (SSTR2 …

In 1972, Brazeau et al. isolated somatostatin (somatotropin release-inhibiting factor, SRIF), a
cyclic polypeptide with two biologically active isoforms (SRIF-14 and SRIF-28). This event …

Background There is a need for novel antitumor agents that demonstrate efficacy in currently
refractory tumors without adding to the toxicity of therapy. The somatostatin analogs, which …